Tenor Capital Management’s Silexion Therapeutics Warrant SLXNW Stock Holding History
Bought
Maintained
Sold
Other funds holding SLXNW
DCM
Tenor Capital Management's SLXNW Position: Q3 2026 in Review
Tenor Capital Management held its Silexion Therapeutics Warrant (SLXNW) position steady in Q3 2026 at 50,000 shares worth $255. The position accounts for ﹤0.01% of the portfolio, ranked #592.
Tenor Capital Management first reported a position in SLXNW in Q3 2024 and has held it in 9 quarters since. The position peaked at $3.82K in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q3 2026.
- Tenor Capital Management held 50,000 shares of Silexion Therapeutics Warrant worth $255 as of Q3 2026.
- Tenor Capital Management left its Silexion Therapeutics Warrant share count unchanged in Q3 2026.
- Silexion Therapeutics Warrant made up ﹤0.01% of Tenor Capital Management's portfolio in Q3 2026, its #592 holding.
- Tenor Capital Management first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 9 quarters since.
- Tenor Capital Management's Silexion Therapeutics Warrant position peaked at $3.82K in Q1 2025.
- 19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q3 2026.
Based on Tenor Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.